G1 to S phase transition 1Genealiases: 551G9.2 · ETF3A · GST1 · eRF3a
Q-omics provides the consensus-scored GSPT1 profile across patient tissues and cancer cell-line models. GSPT1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GSPT1 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, GSPT1 protein abundance shows 23,764 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight MESO, LIHC, and CCRCC as cancer lineages where GSPT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GSPT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GSPT1 survival associations across molecular data types. GSPT1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GSPT1 RNA expression–survival associations across cancer types. High GSPT1 expression shows unfavorable associations in MESO, PAAD and LIHC, but favorable associations in KIRC, READ and COAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for GSPT1 RNA expression.
This table summarizes GSPT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for GSPT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GSPT1 shows lower tumor expression in THCA and higher tumor expression in LIHC, COAD, STAD, HNSC and BRCA. The LIHC box plot shows higher GSPT1 RNA expression in tumor versus normal tissue (log2 FC = +0.911, t-test p < 0.001).
This table shows molecular features associated with GSPT1 in patient tissues and cancer cell lines. In patient samples, GSPT1 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GSPT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
